Drug Type Bispecific antibody |
Synonyms- |
Target |
Action agonists, antagonists |
Mechanism DR4 agonists(Tumor necrosis factor receptor superfamily member 10A agonists), FAP antagonists(Fibroblast activation protein alpha antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 28 Aug 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Japan | 28 Aug 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Spain | 28 Aug 2024 | |
Metastatic Solid Tumor | Phase 1 | United States | 28 Aug 2024 | |
Metastatic Solid Tumor | Phase 1 | Japan | 28 Aug 2024 | |
Metastatic Solid Tumor | Phase 1 | Spain | 28 Aug 2024 | |
Solid tumor | Preclinical | Netherlands | 28 Apr 2025 |